证券代码：600129 证券简称：太极集团 公告编号：2025-039 重庆太极实业（集团）股份有限公司 关于监事辞职的公告 特此公告。 重庆太极实业（集团）股份有限公司 2025 年 5 月 28 日 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重庆太极实业（集团）股份有限公司（以下简称"公司"）监事 会于近日收到徐庭梅女士的辞职报告。因工作原因，徐庭梅女士申请 辞去公司第十届监事会职工代表监事职务，辞职后，徐庭梅女士仍为 公司下属子公司员工。 根据《公司法》及《公司章程》等相关规定，徐庭梅女士的辞职 未导致公司监事会人数低于法定最低人数，不会影响监事会正常运作， 其辞职报告自送达监事会时生效。 公司及公司监事会对徐庭梅女士在任职期间为公司发展所做的 贡献表示衷心感谢。 ...

Group 1 - A-share pharmaceutical stocks are active at the beginning of trading, with Zhongsheng Pharmaceutical and Haisen Pharmaceutical hitting the daily limit [1] - Haichen Pharmaceutical, Huason Pharmaceutical, Taiji Group, and Duori Pharmaceutical also experienced gains [1]

Group 1 - The 7th China Western International Investment and Trade Fair (West Expo) will be held in Chongqing from May 22 to 25, 2025, focusing on key industrial chains such as advanced materials, new energy power batteries, food and agricultural product processing, shale gas and clean energy, and modern services [1] - The Fuling exhibition hall will feature a theme of "Empowering Innovation, Promoting Industry," showcasing a 552 square meter immersive display space that highlights the Fuling "2349" modern manufacturing cluster system [3] - Fuling District will organize 51 enterprises to participate in the exhibition, including two "billion-level" leading industrial clusters, three "500 billion" pillar industrial clusters, four "100 billion" characteristic advantage industrial sectors, and nine "new star" industrial clusters [4] Group 2 - During the West Expo, Fuling District's delegation will engage in multiple activities, resulting in six signed projects with a total agreement amount of 16.207 billion yuan, covering industries such as energy, intelligent equipment, food and agricultural products, new materials, and transportation logistics [6] - Fuling District will showcase its modern urban image as a livable and enjoyable place, demonstrating achievements in traditional industry upgrades and emerging technology breakthroughs, while releasing strong development potential [8]

Group 1 - The A-share market indices collectively rose, with the Traditional Chinese Medicine (TCM) ETF (560080) increasing by 1.05%, and several key stocks in the sector, such as Zhongsheng Pharmaceutical and Zhaoli Pharmaceutical, rising over 3% [1] - The recent increase in COVID-19 infection rates has been noted, but experts believe the current wave is manageable and not a cause for panic, with symptoms similar to previous infections [3] - The pharmaceutical and biotechnology sector performed well last week, with the TCM sector leading the sub-sectors in growth, as reported by Donghai Securities [3] Group 2 - The first quarter of 2025 posed challenges for TCM companies, but a potential turning point is expected in the second quarter, driven by factors such as decreased flu incidence and reduced inventory levels [6] - Among TCM companies, nearly half achieved positive growth in net profit, with notable companies like Jiaying Pharmaceutical and Te Yi Pharmaceutical showing significant revenue and profit increases [7] - The inventory levels of TCM companies have decreased, indicating a potential for improved profitability moving forward [7] Group 3 - Institutional holdings in TCM have been declining, with the proportion falling to 0.46% by the first quarter of 2025, suggesting a potential for renewed interest from funds in domestic TCM under current U.S. tariff policies [8] - The current price-to-earnings ratio of the TCM index is 25.7, which is below the 10-year average, indicating that valuations are relatively low [8] Group 4 - Key indicators for TCM include flu data and the price index of medicinal materials, with expectations of reduced revenue growth pressure for TCM companies starting in the second quarter of 2025 [10] - The price index for medicinal materials has been declining, which is expected to alleviate gross margin pressures for TCM companies [10] Group 5 - Investment strategies favoring strong brand power in state-owned enterprises are recommended, as these companies benefit from reforms and have higher dividend yields [12] - A recommended investment portfolio includes TCM companies with improving gross margins and those benefiting from state-owned enterprise reforms [14]

Core Viewpoint - The traditional Chinese medicine (TCM) decoction pieces industry is undergoing a transformation from "experience inheritance" to "scientific verification," driven by the increasing demand for standardized and convenient TCM treatments, which is leading to a capitalized moment in the industry [1] Group 1: Company Overview - Sichuan Xinhehua Chinese Medicine Decoction Pieces Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, aiming to become the "first stock of TCM decoction pieces" in Hong Kong, with over 770 varieties and 4900 specifications of decoction pieces [1][4] - As the second-largest supplier of TCM decoction pieces in China, Xinhehua has established a dual-pillar strategy of "leading position in the core TCM market + disruptive innovation for modern consumers," contributing to the modernization of TCM [1][12] Group 2: Market Changes - The company is capitalizing on four major market changes: the "quality and price" focus of centralized procurement, segmentation of distribution channels, industry specialization, and the evolving health management needs [2] - Recent policies have strengthened support for the TCM industry, with a focus on standardization and centralized procurement, leading to an average price drop of 29.5% for 21 types of decoction pieces across 15 provinces [2][5] Group 3: Product Quality and Standards - Xinhehua is the first TCM decoction pieces company in China to obtain GMP certification and has participated in the formulation of 31 national processing standards and 7 major TCM material specifications, ensuring product quality and safety [3][4] - The company has also contributed to the revision of national standards for specific TCM materials, integrating modern scientific technology into production and quality assessment [4] Group 4: Financial Performance - Xinhehua's revenue has grown from 780 million yuan in 2022 to 1.249 billion yuan in 2024, with a compound annual growth rate of 27% [9] - The company's operational efficiency is reflected in its reduced sales and financial expense ratios, which have decreased by 1.68 percentage points and 0.22 percentage points, respectively, from 2022 to 2024 [9] Group 5: Future Prospects - The market size of TCM decoction pieces reached 278.8 billion yuan in 2023 and is expected to exceed 400 billion yuan by 2030, indicating a promising outlook for the industry [12] - Xinhehua's strategy focuses on maintaining its leadership in the core TCM market while innovating for modern consumers, positioning itself to capture new growth opportunities in the TCM decoction pieces sector [12]

一、 会议召开和出席情况 证券代码：600129 证券简称：太极集团 公告编号：2025-038 重庆太极实业（集团）股份有限公司 2024年年度股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 (一)股东会召开的时间：2025 年 5 月 15 日 (二)股东会召开的地点：重庆市渝北区恒山东路 18 号公司 1201 会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 494 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 202,503,483 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 36.3632 | (四)表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况等。 本次股东大会由董事会召集，会议由董事兼总经理于宗斌先生主持，本次会议的 召集、召开及表决方式均符合《公司法》及《公司章程》的有关规 ...

重庆源伟律师事务所 关于重庆太极实业（集团）股份有限公司 2024 年年度股东大会的法律意见书 致：重庆太极实业（集团）股份有限公司 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共 和国证券法》、中国证券监督管理委员会发布的《上市公司股东会规则》（以下 简称"《股东会规则》"）和《上海证券交易所上市公司自律监管指引第 1 号-- 规范运作》等法律、行政法规、规范性文件以及《重庆太极实业（集团）股份 有限公司章程》（以下简称"《公司章程》"）的规定，重庆源伟律师事务所(以 下简称"本所")接受重庆太极实业（集团）股份有限公司（以下简称"公司") 的委托，指派程源伟、谢申丽律师出席公司于 2025 年 5 月 15 日 14 点 00 分在 重庆市渝北区恒山东路 18 号公司 1201 会议室召开的 2024 年年度股东大会(以 下简称"本次股东大会")，对本次股东大会的召集、召开程序的合法性、召集 人和出席会议人员资格的合法有效性、会议表决程序和表决结果的合法有效性 出具法律意见书。 为出具本法律意见书，本所律师对本次股东大会所涉及的有关事项进行了审 查，查阅了本所律师认为出具法律意见所必 ...

广发证券联席 首席金工分析师 陈原文 SAC: S0260517080003 chenyuanwen@gf.com.cn 广发证券首席金工分析师 安宁宁 SAC: S0260512020003 anningning@gf.com.cn 广发证券资深金工分析师 张钰东 SAC: S0260522070006 zhangyudong@gf.com.cn 广发金工安宁宁陈原文团队 摘要 研究背景： 近年来，指数化投资理念愈发受到投资者认可。根据指数编制规则，上证50、沪深300和中证500等宽基指数于每年的6月和12月定期调仓，成 分股名单会部分调入调出。跟踪相应指数的指数型基金，同样会参照指数编制规则，被动调整持仓成分股。当前的被动型基金规模屡创新高，若指数成分 股存在较大变动，则可能带来潜在的投资机会。 指数类产品规模统计： 规模继续增长。根据Wind，截至4月30日，1969只被动指数型基金（ETF和场外被动指数型基金）规模合计3.4万亿元，346只增强 指数型基金规模合计2211亿元，合计规模高于偏股混合型基金（2.07万亿元）。根据跟踪指数的不同，统计各类指数的产品跟踪情况，跟踪指数产品规模 靠前的指数分 ...

Core Viewpoint - The financial report of Pianzaihuang for 2024 reveals significant challenges, with a 26.07% year-on-year decline in net profit for Q4, marking the lowest level since 2019, and a record low revenue growth of 7.25% over the past decade, reflecting broader difficulties faced by the traditional Chinese medicine industry [2][8]. Industry Situation - The primary challenge for Pianzaihuang is the rising cost of raw materials, particularly natural cow bile, which has surged from 650,000 yuan per kilogram to 1,650,000 yuan per kilogram over the past two years [3]. - The overall Chinese medicine sector is experiencing a collective downturn, with Pianzaihuang being relatively better off compared to other companies like Zhongsheng Pharmaceutical and Taiji Group, which reported drastic profit declines [7][8]. Financial Performance - Pianzaihuang's Q4 net profit was 290 million yuan, down 26.07% year-on-year, while the annual revenue growth was only 7.25%, the lowest in a decade [2][4]. - The company attempted to mitigate rising costs by increasing prices by 28.8% in 2023, but revenue and net profit growth rates fell to 15.69% and 13.04%, respectively, in the same year [4][5]. Cost Structure - Direct material costs account for over 90% of the total costs in various product categories, including liver disease and cardiovascular medications, indicating a heavy reliance on raw materials [4][7]. - The cost of direct materials for liver disease medications reached 164.48 million yuan, representing 96.52% of total costs, while cardiovascular medications saw a 56.1% increase in material costs year-on-year [4]. Market Dynamics - The price of Pianzaihuang's product has reached the upper limit of consumer acceptance, with retail prices significantly lower than the official price, indicating challenges in passing on costs to consumers [5]. - The collective "explosion" in the Chinese medicine sector is attributed to policy changes, including the expansion of centralized procurement, which has led to significant price reductions and profit declines for many companies [9][15]. Future Outlook - The Chinese medicine industry must address the impacts of centralized procurement policies, which have resulted in price drops and profit squeezes, while also focusing on innovation and diversification to mitigate risks associated with raw material costs [16][17]. - Companies like Pianzaihuang are exploring diversification strategies, but the effectiveness of these efforts remains limited, highlighting the need for a more robust approach to research and development [17][18].

目录 | 一、公司《2024 | 年度董事会工作报告》 3 | | --- | --- | | 二、公司《2024 | 年度监事会工作报告》 15 | | 三、公司《2024 | 年年度报告及年度报告摘要》 22 | | 四、公司《2024 | 年度财务决算报告》 34 | | 五、关于公司 | 2024 年度利润分配的议案 42 | | 六、关于申请公司 | 2025 年度综合授信的案 43 | | 七、听取公司 | 2024 年度独立董事述职告 45 | 重庆太极实业（集团）股份有限公司 2024 年年度股东大会会议资料 重庆太极实业（集团）股份有限公司 2024 年年度股东大会资料 2025 年 5 月 重庆太极实业（集团）股份有限公司 2024 年年度股东大会会议资料 1 重庆太极实业（集团）股份有限公司 2024 年年度股东大会会议资料 重庆太极实业（集团）股份有限公司 2024 年年度股东大会议程 三、到会股东审议如下议案： 重庆太极实业（集团）股份有限公司 2025 年 5 月 15 日 2 一、主持人宣布会议开始； 二、主持人报告股东现场到会情况； 1.公司《2024 年度董事会工作报告》； ...